Skip to Main Content

Paper Details

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
BMC Cancer
2
2021
Author NameAffiliation
Andy KaempfKnight Cancer Institute, Oregon Health & Science University
  • 1 - 1

Datasets

Release 1.2